Contents

Search

PROVE-IT study

4162 patients hospitalized with acute coronary syndrome Patients randomized to: - pravastatin 40 mg or atorvastatin 80 mg daily At 24 months, median LDL cholesterol levels - 95 mg/dL in pravastatin group - 62 mg/dL in atorvastatin group Combined endpoint of: - death, myocardial infarction, unstable angina, stroke, revascularization Results: 1) combined endpoint reached less frequently in atorvastin group 22% vs 26% 2) lower LDL cholesterol & lower CRP levels independently associated with better outcomes

Related

Reversal of Atherosclerosis with Aggressive Lipid Lowering [REVERSAL] study

General

clinical trial

References

  1. Journal Watch 24(9):69-70, 2004 Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 8;350(15):1495-504. Epub 2004 Mar 08. PMID: 15007110
  2. Journal Watch 25(3):21, 2005 Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 6;352(1):20-8. PMID: 15635109